Relay Therapeutics
RLAY · NASDAQ · Healthcare
$18.03
$0.16 (-0.88%) today
Market Cap
$3.95B
24h Volume
$84.8M
P/E Ratio
0.0
52w High
$20.75
52w Low
$4.38
Est. AI Revenue
100%
7-Day Sparkline (Static)
Company facts
Performance
About Relay Therapeutics
Relay Therapeutics is an AI-native biotech developing precision cancer medicines. Its Dynamo platform combines physics-based simulations of how proteins move with machine learning, aiming to design drugs against targets that conventional methods struggle to hit.
The platform is the product pipeline's engine: protein motion simulation models how disease targets behave in motion, ML-guided lead optimization refines drug candidates, and structure-based drug design AI turns those insights into molecules that enter clinical development.
Founded in 2016 and headquartered in Cambridge, Massachusetts, Relay trades on the NASDAQ and employs about 190 people under CEO Sanjiv Patel.
Relay Therapeutics in the AI buildout
Relay sits in the AI Healthcare layer as a computational-first drug company. It exists on the premise that simulating protein motion plus machine learning can find medicines others cannot, which makes AI foundational to everything it does. The catch is that value ultimately hinges on clinical trial results, not compute demand: the AI has to produce drugs that work in patients. Supercycle scores its AI exposure at 70 out of 100.
RLAY is tracked in AI Healthcare, rated Core on the AI Exposure leaderboard.
By the numbers
52-week range
RLAY trades at $18.03, 83% of the way up its 52-week range of $4.38 to $20.75.
Market cap
Market capitalization is $3.95B, with an AI Exposure Score of 70 out of 100.
Next earnings
Relay Therapeutics is next expected to report earnings on November 5, 2026.
Market data as of the close on . Prices are end of day, not live.
Frequently asked questions
What does Relay Therapeutics do?
Relay is a biotech developing precision cancer medicines. Its Dynamo platform combines physics-based protein motion simulation with machine learning to design drugs against difficult targets, feeding its oncology pipeline.
How is Relay exposed to AI?
Foundationally. The company was built as a computational-first biotech, with AI and simulation at the core of how it discovers drugs. Supercycle rates its AI Exposure Score at 70 out of 100.
What is the Dynamo platform?
Dynamo is Relay's drug discovery engine. It simulates how proteins move, applies machine learning to guide lead optimization, and uses structure-based AI design to create drug candidates against targets that static approaches miss.
Is RLAY a pure play AI stock?
Nearly, within biotech. AI drug discovery is the company's entire identity, but its value ultimately depends on clinical trial results rather than AI demand. Its AI Exposure Score is 70 out of 100.
Where is Relay based and who leads it?
Relay Therapeutics is headquartered in Cambridge, Massachusetts, and led by CEO Sanjiv Patel. Founded in 2016, it is a focused team of about 190 people trading on the NASDAQ.
Profile written 2026-08, updated as the business changes. Editorial content, not investment advice.